StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)

Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%

Eli Lilly Erbitux (cetuximab) by Quarter

Erbitux (cetuximab) — Worldwide revenue ($M) [legacy separate disclosure] ($M)

QuarterlyAnnual

Eli Lilly Erbitux (cetuximab): $175M in Q4 2024, up 16.5% from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2024
175
Period ended Dec 31, 2024
Change on a year earlier
+16.5%
150 in Q4 2023
History
55 quarters
Since Q3 2009
Sources
48
Documents cited below

Where the Q4 2024 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K FY2024 (filed 2025-02-19) ↗

Reported in Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedErbitux (cetuximab) — Worldwide revenue ($M) [legacy separate disclosure] ($M)Year on yearSource
Q4 2024Dec 31, 2024175+16.5%Form 10-K FY2024 (filed 2025-02-19) ↗
Q3 2024Sep 30, 2024152-1.2%Form 10-Q (filed 2024-10-30) ↗
Q2 2024Jun 30, 2024156-4.1%Form 10-Q (filed 2024-08-08) ↗
Q1 2024Mar 31, 2024145+11.3%Form 10-Q (filed 2024-04-30) ↗
Q4 2023Dec 31, 2023150-5.1%Form 10-K FY2023 (filed 2024-02-21) ↗
Q3 2023Sep 30, 2023154+6.2%Form 10-Q (filed 2024-10-30) ↗
Q2 2023Jun 30, 2023163+15.4%Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 2023130+5.9%Form 10-Q (filed 2024-04-30) ↗
Q4 2022Dec 31, 2022158+9.4%Form 10-K FY2022 (filed 2023-02-22) ↗
Q3 2022Sep 30, 2022145+7.9%Form 10-Q (filed 2023-11-02) ↗
Q2 2022Jun 30, 2022141-4.2%Form 10-Q (filed 2023-08-08) ↗
Q1 2022Mar 31, 2022123+0.2%Form 10-Q (filed 2023-04-27) ↗
Q4 2021Dec 31, 2021145+3.5%Form 10-K FY2021 (filed 2022-02-23) ↗
Q3 2021Sep 30, 2021134-1.5%Form 10-Q (filed 2022-11-01) ↗
Q2 2021Jun 30, 2021147+13.5%Form 10-Q (filed 2022-08-04) ↗
Q1 2021Mar 31, 2021122-6.4%Form 10-Q (filed 2022-04-29) ↗

Breakdown

What makes up erbitux (cetuximab)

Cite this data

StockData. (2026). Eli Lilly Erbitux (cetuximab) ($M), quarterly Q3 2009–Q4 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-erbitux-ww

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.